1Draeger E. Clinical profile of glimepiride[J]. Diabet Res Clin Pract, 1995, 28: 139.
2Campbell R K. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[J]. Ann Pharmacother, 1998, 32: 1044.
3Massi-Benedeti M, Herz M. Pfeiffer C. The effects of acute exercise on metabolic control in type 2 diabetic patients treated with glimepiride or glibenclamide[J]. Horm Metab Res, 1996, 28: 451.
3[3]John R,White JR.The pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus[J].Clinical Diabetes,1998,16:2.
4Plosker G L, Figgitt D P. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus[J]. Pharmacoeconomics, 2004, 22(6): 389.
5Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoqlycaemic agents, NN623 and A4166[J]. Diabe Med, 1996, 13: 151.
6Lider T R. FDA approves nateglinide for treatment of type 2 diabetes[J]. Am J Health Syst Pharm, 2001, 58(4): 285.
7Bonow R O, Gheorghiade M. The diabetes epidemic: a national and global crisis[J]. Am J Med, 2004, 116 Suppl 5A: 2S.
8Sunaga Y, Gonoi T, Shibasaki T. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide[J]. Eur J Pharmacol, 2001, 431(1): 119.
9Owens D R. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic druges[J]. Diabetes Med. 1998, 15(Suppl 4): S28.
10Malaisse W J. Meglitinide analogs: new insulinotropic agents for the treatment of non-insulin dependent diabetes[J]. Rev Med Brux, 2003, 24(3): 162.
